In vitro effects of the small-molecule protein kinase C agonists on HIV latency reactivation

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Brogdon, Jessica ^a   Ziani, Widade ^a   Wang, Xiaolei ^a   Veazey, Ronald S ^a   Xu, Huanbin ^a  

^a TULANE NATIONAL PRIMATE RESEARCH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENZYME ACTIVATOR; PROTEIN KINASE C;

ANIMAL; CHEMISTRY; DRUG EFFECT; ENZYMOLOGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; JURKAT CELL LINE; METABOLISM; PHYSIOLOGY; RHESUS MONKEY; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; VIRUS ACTIVATION; VIRUS LATENCY;

ANIMALS; ENZYME ACTIVATORS; HIV INFECTIONS; HIV-1; HUMANS; JURKAT CELLS; MACACA MULATTA; PROTEIN KINASE C; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; VIRUS ACTIVATION; VIRUS LATENCY;

EID: 85006007491     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep39032     Document Type: Article

References (69)

1. Barouch, D. H., Deeks, S. G. Immunologic strategies for HIV-1 remission and eradication. Science 345, 169-174, doi: 10. 1126/science. 1255512 (2014).
2. Finzi, D. et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 278, 1295-1300 (1997).
3. Siliciano, J. D. et al. Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nature medicine 9, 727-728, doi: 10. 1038/nm880 (2003).
4. Strain, M. C. et al. Heterogeneous clearance rates of long-lived lymphocytes infected with HIV: intrinsic stability predicts lifelong persistence. Proc Natl Acad Sci USA 100, 4819-4824, doi: 10. 1073/pnas. 0736332100 (2003).
5. Chun, T. W., Davey, R. T. Jr., Engel, D., Lane, H. C., Fauci, A. S. Re-emergence of HIV after stopping therapy. Nature 401, 874-875, doi: 10. 1038/44755 (1999).
6. Dinoso, J. B. et al. A simian immunodeficiency virus-infected macaque model to study viral reservoirs that persist during highly active antiretroviral therapy. Journal of virology 83, 9247-9257, doi: 10. 1128/JVI. 00840-09 (2009).
7. Geeraert, L., Kraus, G., Pomerantz, R. J. Hide-and-seek: the challenge of viral persistence in HIV-1 infection. Annu Rev Med 59, 487-501, doi: 10. 1146/annurev. med. 59. 062806. 123001 (2008).
8. Xu, H. et al. Persistent Simian Immunodeficiency Virus Infection Drives Differentiation, Aberrant Accumulation, and Latent Infection of Germinal Center Follicular T Helper Cells. Journal of virology 90, 1578-1587, doi: 10. 1128/JVI. 02471-15 (2015).
9. Connick, E. et al. Compartmentalization of Simian Immunodeficiency Virus Replication within Secondary Lymphoid Tissues of Rhesus Macaques Is Linked to Disease Stage and Inversely Related to Localization of Virus-Specific CTL. J Immunol 193, 5613-5625, doi: 10. 4049/jimmunol. 1401161 (2014).
10. Blankson, J. N., Persaud, D., Siliciano, R. F. The challenge of viral reservoirs in HIV-1 infection. Annu Rev Med 53, 557-593, doi: 10. 1146/annurev. med. 53. 082901. 104024 (2002).
11. Chun, T. W., Engel, D., Mizell, S. B., Ehler, L. A., Fauci, A. S. Induction of HIV-1 replication in latently infected CD4+ T cells using a combination of cytokines. J Exp Med 188, 83-91 (1998).
12. van Praag, R. M. et al. OKT3 and IL-2 treatment for purging of the latent HIV-1 reservoir in vivo results in selective long-lasting CD4+ T cell depletion. J Clin Immunol 21, 218-226 (2001).
13. Moriuchi, H., Moriuchi, M., Mizell, S. B., Ehler, L. A., Fauci, A. S. In vitro reactivation of human immunodeficiency virus 1 from latently infected, resting CD4+ T cells after bacterial stimulation. J Infect Dis 181, 2041-2044, doi: 10. 1086/315496 (2000).
14. Shen, Y. et al. Clinical latency and reactivation of AIDS-related mycobacterial infections. J Virol 78, 14023-14032, doi: 10. 1128/JVI. 78. 24. 14023-14032. 2004 (2004).
15. Sahu, G. K. et al. Anti-HIV designer T cells progressively eradicate a latently infected cell line by sequentially inducing HIV reactivation then killing the newly gp120-positive cells. Virology 446, 268-275, doi: 10. 1016/j. virol. 2013. 08. 002 (2013).
16. Rasmussen, T. A., Tolstrup, M., Sogaard, O. S. Reversal of Latency as Part of a Cure for HIV-1. Trends Microbiol 24, 90-97, doi: 10. 1016/j. tim. 2015. 11. 003 (2016).
17. Bullen, C. K., Laird, G. M., Durand, C. M., Siliciano, J. D., Siliciano, R. F. New ex vivo approaches distinguish effective and ineffective single agents for reversing HIV-1 latency in vivo. Nat Med 20, 425-429, doi: 10. 1038/nm. 3489 (2014).
18. Deeks, S. G. HIV: Shock and kill. Nature 487, 439-440, doi: 10. 1038/487439a (2012).
19. Archin, N. M., Margolis, D. M. Emerging strategies to deplete the HIV reservoir. Current opinion in infectious diseases 27, 29-35, doi: 10. 1097/QCO. 0000000000000026 (2014).
20. Archin, N. M. et al. Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature 487, 482-485, doi: 10. 1038/nature11286 (2012).
21. Archin, N. M. et al. Immediate antiviral therapy appears to restrict resting CD4+ cell HIV-1 infection without accelerating the decay of latent infection. Proc Natl Acad Sci USA 109, 9523-9528, doi: 10. 1073/pnas. 1120248109 (2012).
22. Del Prete, G. Q. et al. Effect of suberoylanilide hydroxamic acid (SAHA) administration on the residual virus pool in a model of combination antiretroviral therapy-mediated suppression in SIVmac239-infected indian rhesus macaques. Antimicrob Agents Chemother 58, 6790-6806, doi: 10. 1128/AAC. 03746-14 (2014).
23. Danaher, R. J. et al. Histone deacetylase inhibitors induce reactivation of herpes simplex virus type 1 in a latency-associated transcript-independent manner in neuronal cells. J Neurovirol 11, 306-317, doi: 10. 1080/13550280590952817 (2005).
24. Krishna, B. A. et al. Transient activation of human cytomegalovirus lytic gene expression during latency allows cytotoxic T cell killing of latently infected cells. Sci Rep 6, 24674, doi: 10. 1038/srep24674 (2016).
25. DeChristopher, B. A. et al. Designed, synthetically accessible bryostatin analogues potently induce activation of latent HIV reservoirs in vitro. Nat Chem 4, 705-710, doi: 10. 1038/nchem. 1395 (2012).
26. Cary, D. C., Peterlin, B. M. Targeting the latent reservoir to achieve functional HIV cure. F1000Res 5, doi: 10. 12688/f1000research. 8109. 1 (2016).
27. Beans, E. J. et al. Highly potent, synthetically accessible prostratin analogs induce latent HIV expression in vitro and ex vivo. Proc Natl Acad Sci USA 110, 11698-11703, doi: 10. 1073/pnas. 1302634110 (2013).
28. Hampson, P. et al. PEP005, a selective small-molecule activator of protein kinase C, has potent antileukemic activity mediated via the delta isoform of PKC. Blood 106, 1362-1368, doi: 10. 1182/blood-2004-10-4117 (2005).
29. Fidler, B., Goldberg, T. Ingenol mebutate gel (picato): a novel agent for the treatment of actinic keratoses. P T 39, 40-46 (2014).
30. Li, L. et al. The skin cancer chemotherapeutic agent ingenol-3-angelate (PEP005) is a substrate for the epidermal multidrug transporter (ABCB1) and targets tumor vasculature. Cancer Res 70, 4509-4519, doi: 10. 1158/0008-5472. CAN-09-4303 (2010).
31. Kim, H. S. et al. A randomized prospective trial of the postoperative quality of life between laparoscopic uterine artery ligation and laparoscopy-assisted vaginal hysterectomy for the treatment of symptomatic uterine fibroids: clinical trial design. Trials 10, 8, doi: 10. 1186/1745-6215-10-8 (2009).
32. Jiang, G. et al. Synergistic Reactivation of Latent HIV Expression by Ingenol-3-Angelate, PEP005, Targeted NF-kB Signaling in Combination with JQ1 Induced p-TEFb Activation. PLoS Pathog 11, e1005066, doi: 10. 1371/journal. ppat. 1005066 (2015).
33. Warrilow, D., Gardner, J., Darnell, G. A., Suhrbier, A., Harrich, D. HIV type 1 inhibition by protein kinase C modulatory compounds. AIDS Res Hum Retroviruses 22, 854-864, doi: 10. 1089/aid. 2006. 22. 854 (2006).
34. Spivak, A. M. et al. Ex Vivo Bioactivity and HIV-1 Latency Reversal by Ingenol Dibenzoate and Panobinostat in Resting CD4(+ ) T Cells from Aviremic Patients. Antimicrob Agents Chemother 59, 5984-5991, doi: 10. 1128/AAC. 01077-15 (2015).
35. Williams, S. A. et al. Prostratin antagonizes HIV latency by activating NF-kappaB. J Biol Chem 279, 42008-42017, doi: 10. 1074/jbc. M402124200 (2004).
36. Biancotto, A. et al. Dual role of prostratin in inhibition of infection and reactivation of human immunodeficiency virus from latency in primary blood lymphocytes and lymphoid tissue. J Virol 78, 10507-10515, doi: 10. 1128/JVI. 78. 19. 10507-10515. 2004 (2004).
37. Witvrouw, M. et al. Potent and selective inhibition of HIV and SIV by prostratin interacting with viral entry. Antivir Chem Chemother 14, 321-328 (2003).
38. Sanchez-Duffhues, G. et al. Activation of latent HIV-1 expression by protein kinase C agonists. A novel therapeutic approach to eradicate HIV-1 reservoirs. Curr Drug Targets 12, 348-356 (2011).
39. Hezareh, M. Prostratin as a new therapeutic agent targeting HIV viral reservoirs. Drug News Perspect 18, 496-500, doi: 10. 1358/dnp. 2005. 18. 8. 944543 (2005).
40. Zhang, X. et al. Preclinical pharmacology of the natural product anticancer agent bryostatin 1, an activator of protein kinase C. Cancer Res 56, 802-808 (1996).
41. Amador, M. L., Jimeno, J., Paz-Ares, L., Cortes-Funes, H., Hidalgo, M. Progress in the development and acquisition of anticancer agents from marine sources. Ann Oncol 14, 1607-1615 (2003).
42. Mehla, R. et al. Bryostatin modulates latent HIV-1 infection via PKC and AMPK signaling but inhibits acute infection in a receptor independent manner. PLoS One 5, e11160, doi: 10. 1371/journal. pone. 0011160 (2010).
43. Gutierrez, C. et al. Bryostatin-1 for latent virus reactivation in HIV-infected patients on antiretroviral therapy. AIDS 30, 1385-1392, doi: 10. 1097/QAD. 0000000000001064 (2016).
44. Martinez-Bonet, M. et al. Synergistic Activation of Latent HIV-1 Expression by Novel Histone Deacetylase Inhibitors and Bryostatin-1. Sci Rep 5, 16445, doi: 10. 1038/srep16445 (2015).
45. Darcis, G. et al. An In-Depth Comparison of Latency-Reversing Agent Combinations in Various In Vitro and Ex Vivo HIV-1 Latency Models Identified Bryostatin-1+ JQ1 and Ingenol-B+ JQ1 to Potently Reactivate Viral Gene Expression. PLoS Pathog 11, e1005063, doi: 10. 1371/journal. ppat. 1005063 (2015).
46. Diaz, L. et al. Bryostatin activates HIV-1 latent expression in human astrocytes through a PKC and NF-kB-dependent mechanism. Sci Rep 5, 12442, doi: 10. 1038/srep12442 (2015).
47. Walker-Sperling, V. E., Pohlmeyer, C. W., Tarwater, P. M., Blankson, J. N. The Effect of Latency Reversal Agents on Primary CD8+ T Cells: Implications for Shock and Kill Strategies for Human Immunodeficiency Virus Eradication. EBioMedicine 8, 217-229, doi: 10. 1016/j. ebiom. 2016. 04. 019 (2016).
48. Laird, G. M. et al. Ex vivo analysis identifies effective HIV-1 latency-reversing drug combinations. J Clin Invest 125, 1901-1912, doi: 10. 1172/JCI80142 (2015).
49. Loven, J. et al. Selective inhibition of tumor oncogenes by disruption of super-enhancers. Cell 153, 320-334, doi: 10. 1016/j. cell. 2013. 03. 036 (2013).
50. Boehm, D. et al. BET bromodomain-targeting compounds reactivate HIV from latency via a Tat-independent mechanism. Cell Cycle 12, 452-462, doi: 10. 4161/cc. 23309 (2013).
51. Li, Z., Guo, J., Wu, Y., Zhou, Q. The BET bromodomain inhibitor JQ1 activates HIV latency through antagonizing Brd4 inhibition of Tat-transactivation. Nucleic Acids Res 41, 277-287, doi: 10. 1093/nar/gks976 (2013).
52. Vemula, S. V. et al. HIV-1 induced nuclear factor I-B (NF-IB) expression negatively regulates HIV-1 replication through interaction with the long terminal repeat region. Viruses 7, 543-558, doi: 10. 3390/v7020543 (2015).
53. Jordan, A., Defechereux, P., Verdin, E. The site of HIV-1 integration in the human genome determines basal transcriptional activity and response to Tat transactivation. EMBO J 20, 1726-1738, doi: 10. 1093/emboj/20. 7. 1726 (2001).
54. Jordan, A., Bisgrove, D., Verdin, E. HIV reproducibly establishes a latent infection after acute infection of T cells in vitro. EMBO J 22, 1868-1877, doi: 10. 1093/emboj/cdg188 (2003).
55. Barski, A. et al. High-resolution profiling of histone methylations in the human genome. Cell 129, 823-837, doi: 10. 1016/j. cell. 2007. 05. 009 (2007).
56. Ferrari, K. J. et al. Polycomb-dependent H3K27me1 and H3K27me2 regulate active transcription and enhancer fidelity. Mol Cell 53, 49-62, doi: 10. 1016/j. molcel. 2013. 10. 030 (2014).
57. Contreras, X. et al. Suberoylanilide hydroxamic acid reactivates HIV from latently infected cells. J Biol Chem 284, 6782-6789, doi: 10. 1074/jbc. M807898200 (2009).
58. Wei, D. G. et al. Histone deacetylase inhibitor romidepsin induces HIV expression in CD4 T cells from patients on suppressive antiretroviral therapy at concentrations achieved by clinical dosing. PLoS Pathog 10, e1004071, doi: 10. 1371/journal. ppat. 1004071 (2014).
59. Cillo, A. R. et al. Quantification of HIV-1 latency reversal in resting CD4+ T cells from patients on suppressive antiretroviral therapy. Proc Natl Acad Sci USA 111, 7078-7083, doi: 10. 1073/pnas. 1402873111 (2014).
60. Del Prete, G. Q. et al. Effect of SAHA administration on the residual virus pool in a model of combination antiretroviral therapy-mediated suppression in SIVmac239-infected Indian rhesus macaques. Antimicrob Agents Chemother, doi: 10. 1128/AAC. 03746-14 (2014).
61. Mohammadi, P. et al. Dynamics of HIV latency and reactivation in a primary CD4+ T cell model. PLoS Pathog 10, e1004156, doi: 10. 1371/journal. ppat. 1004156 (2014).
62. Lucera, M. B. et al. The histone deacetylase inhibitor vorinostat (SAHA) increases the susceptibility of uninfected CD4+ T cells to HIV by increasing the kinetics and efficiency of postentry viral events. Journal of virology 88, 10803-10812, doi: 10. 1128/JVI. 00320-14 (2014).
63. Jones, R. B. et al. Histone deacetylase inhibitors impair the elimination of HIV-infected cells by cytotoxic T-lymphocytes. PLoS Pathog 10, e1004287, doi: 10. 1371/journal. ppat. 1004287 (2014).
64. Chun, T. W. et al. HIV-infected individuals receiving effective antiviral therapy for extended periods of time continually replenish their viral reservoir. J Clin Invest 115, 3250-3255, doi: 10. 1172/JCI26197 (2005).
65. Buzon, M. J. et al. HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects. Nat Med 16, 460-465, doi: 10. 1038/nm. 2111 (2010).
66. Llibre, J. M. et al. Treatment intensification with raltegravir in subjects with sustained HIV-1 viraemia suppression: a randomized 48-week study. Antivir Ther 17, 355-364, doi: 10. 3851/IMP1917 (2012).
67. Wu, Y. HIV-1 gene expression: lessons from provirus and non-integrated DNA. Retrovirology 1, 13, doi: 10. 1186/1742-4690-1-13 (2004).
68. Trabucco, S. E. et al. Inhibition of bromodomain proteins for the treatment of human diffuse large B-cell lymphoma. Clin Cancer Res 21, 113-122, doi: 10. 1158/1078-0432. CCR-13-3346 (2015).
69. Filippakopoulos, P. et al. Selective inhibition of BET bromodomains. Nature 468, 1067-1073, doi: 10. 1038/nature09504 (2010).